News and Trends 25 Mar 2025 AbbVie and Genmab: Can a legal battle break a billion-dollar bond? As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute opposing them. March 25, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 7 Mar 2024 Can AbbVie’s legacy live beyond its once best-selling drug Humira? The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company. March 7, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Seven pharma companies form alliance to prepare for future pandemics Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […] July 20, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2023 AbbVie takes step forward in Europe with migraine drug AbbVie says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month. If approved, AbbVie will be the only company to offer a once daily oral […] June 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023 UK approval for AbbVie Crohn’s disease drug AbbVie has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved RINVOQ (upadacitinib), a janus kinase (JAK) inhibitor, for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological agent. […] February 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 AbbVie bets on Anima mRNA modulators to tackle cancer AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. Anima Biotech will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets, providing AbbVie exclusive rights to license and further develop and commercialize the programs. “This collaboration […] January 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Deep Science Ventures and AbbVie to create companies to target inflammatory diseases Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […] November 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Gate Neurosciences emerges from stealth to tackle CNS diseases Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents Formulations of a drug that can help a number of inflammatory diseases including rheumatoid arthritis and Crohn’s disease have been issued patents by the European Patent Office (EPO). The EPO issued two patents that will protect Arecor Therapeutics’ formulations of high-concentration adalimumab until 2038. The company made the announcement today (August 9). Monoclonal antibody Adalimumab, […] August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Positive results for drug combination used to treat rare blood cancer Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 French Juvisé buys gastro product in €400M finance deal French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […] July 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email